Development of Systemic Lupus Erythematosus After Infectious Mononucleosis in a 64-Year-Old Woman.

J Investig Med High Impact Case Rep

White River Health System, Batesville, AR, USA.

Published: August 2021

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by heterogeneous symptoms that can manifest in any organ, and often presents at a young age. Infectious mononucleosis (IM) is the acute clinical manifestation of Epstein-Barr virus (EBV). It is characterized by low-grade fever, malaise, lymphadenopathy, splenomegaly, and occasionally symmetrical arthralgias. It has been proposed that EBV is a trigger for new-onset SLE, and patients with autoimmune disorders such as SLE are more likely to have recurrent IM infections. The patient, a 64-year old Caucasian female who's only past medical history was hypertension, developed several months-long period of vague symptoms, including fatigue, malaise, nausea, and nonbilious vomiting with oral intake. She presented with symmetrical polyarthritis involving the hands and elbows, with no history of arthritis before this episode. At the 5-month follow-up, she presented with worsening arthritis bilaterally in her elbows and in her right knee. For several decades, there has been a theoretical association between EBV and SLE, with EBV thought to be one of the many possible triggers for development of SLE. Based on the disease course, we theorize that the patient's IM and EBV infection led to development of SLE. A small fraction of SLE cases have been reported in literature to be associated with EBV. This case adds to that literature with EBV triggering development of SLE in a seemingly previously asymptomatic patient.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517992PMC
http://dx.doi.org/10.1177/2324709620961613DOI Listing

Publication Analysis

Top Keywords

development sle
12
systemic lupus
8
lupus erythematosus
8
infectious mononucleosis
8
sle
8
ebv
7
development
4
development systemic
4
erythematosus infectious
4
mononucleosis 64-year-old
4

Similar Publications

Systemic lupus erythematosus and pulmonary tuberculosis in a patient developing acute-onset type 1 diabetes.

Diabetol Int

January 2025

Department of Endocrinology and Diabetes, NTT Medical Center Tokyo, 141-86255-9-22 Higashi-Gotanda, Shinagawa-ku, Tokyo Japan.

A 73-year-old Japanese woman was admitted to our hospital with anorexia, weight loss, and fever. A few weeks prior to admission, she became aware of anorexia. She was leukopenic, complement-depleted, and positive for antinuclear antibodies and anti-double stranded DNA antibodies.

View Article and Find Full Text PDF

Objective: This study investigates the barriers and facilitators to sustaining a decision aid (DA) tool for patients with systemic lupus erythematosus (SLE) in routine rheumatology outpatient care across the U.S. The DA was initially developed for assisting Patients with SLE in making informed medication choices by providing personalized information on their treatment process.

View Article and Find Full Text PDF

Several neurological conditions, including transient global amnesia (TGA), may present an isolated sudden-onset temporary amnestic symptom. TGA is a benign, self-remitting neurological condition associated with hippocampal dysfunction. Meanwhile, certain other neurological conditions, such as cerebral ischemic stroke and hippocampal epilepsy, require appropriate therapeutic interventions.

View Article and Find Full Text PDF

Viral warts, a common dermatological condition caused by human papillomavirus infection (HPV) infection, present a particular challenge for systemic lupus erythematosus (SLE) patients due to their compromised immunity, which increases the susceptibility to HPV infection and complicates treatment efforts. Imiquimod, an immunomodulatory agent, has demonstrated efficacy in managing warts. Furthermore, local hyperthermia, a non-invasive therapeutic modality, has demonstrated significant potential in the management of warts.

View Article and Find Full Text PDF

New insights into the long-term adverse effects of antimalarials in patients with systemic lupus erythematosus.

Lupus

January 2025

Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases, Vasculitis and Autoinflammatory Diseases of the Catalan and Spanish Health Systems, Member of the European Reference Centres (ERN) Re-CONNET and RITA, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Catalonia, Spain.

Background: Hydroxychloroquine is recommended for all patients with systemic lupus erythematosus (SLE) because of its efficacy and safety. Previous studies of antimalarial toxicity under non-experimental conditions have often grouped hydroxychloroquine and chloroquine. This study focuses on the long-term toxicity of antimalarial drugs in SLE patients at a single reference centre.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!